Company: CORT
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001628280-25-037005
Chunk: 29

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 29
---
 30, 2025, respectively, compared to $58.7 million and $117.3 million for the comparable periods in 2024. The increases were primarily due to increased employee compensation expenses and expenses related to the advancement of our development programs, partially offset by decreased expenses related to development programs that are nearing completion. 

Three Months Ended June 30,Six Months Ended June 30, 2025202420252024(in thousands)Development programs:  Oncology$11,061 $11,545 $19,360 $29,230 Hypercortisolism (Cushing’s syndrome)20,334 14,845 38,307 25,657 Metabolic diseases11,647 8,519 22,731 19,508 Pre-clinical and early-stage selective cortisol modulators and ALS4,952 11,775 13,654 20,445 Unallocated activities, including manufacturing and regulatory activities7,080 7,624 15,436 14,053 Stock-based compensation5,397 4,437 11,718 8,358 Total research and development expense$60,471 $58,745 $121,206 $117,251 

It is difficult to predict the timing and cost of development activities, which are subject to many uncertainties and risks, including inconclusive or negative results, slow patient enrollment, adverse side effects and difficulties in the formulation or manufacture of study drugs and lack of drug-candidate efficacy. In addition, clinical development is subject to government oversight and regulations that may change without notice. We expect our research and development expense to be higher in 2025 than in 2024 as our clinical programs advance and we initiate new clinical trials. Research and development spending in future years will depend on the outcome of our pre-clinical and clinical trials and our development plans.

Selling, general and administrative expense – Selling, general and administrative expense includes (1) compensation of employees, consultants and contractors engaged in commercial and administrative activities, (2) the cost of vendors supporting commercial activities and (3) legal and accounting fees.

22

Selling, general and administrative expense was $103.9 million and $194.5 million for the three and six months ended June 30, 2025, respectively, compared to $66.9 million and $123.2 million for the comparable periods in 2024. The increases were primarily due to increased employee